| Founded | 2007 |
|---|---|
| Closed | 2021 |
| Country | USA |
| Sector | Biotech |
| Collapse type | Silent Shutdown |
| Founder | Elliot Danforth |
Melior Pharmaceuticals
"Novel diabetes mechanism, modest Phase 2a results, and a decisive Phase 2b failure ended Melior's 14-year quest."
Quiet closure with no public announcement
Key Events Timeline
Melior Pharmaceuticals developed MLR-1023, a small molecule activator of Lyn kinase, as an oral type 2 diabetes treatment with a novel mechanism.
// full analysis
Full analysis requires the Analyst plan
Documented cause · Market cycle · Competitive moat type · Verified lesson
€149/mo · or contribute your autopsy for free access →
UnicornBurn Season 0 opens July 2026. 10,000 founders competing in one world. Your startup fights for the market every Saturday. Most will end up here. Which one are you?
JOIN SEASON 0 →Melior Pharmaceuticals followed a documented pattern. Identify the same signals in any company before they reach the point of no return.
Witnessed a startup failure first-hand? Share the real story. First-hand accounts from founders and team members get prioritized for publication.
SUBMIT AN AUTOPSY →Failure intelligence for due diligence and risk analysis.
Structured dataset by collapse type, for 5031 startups. 7-day trial.
See plans →Free JSON API. No key required. 50 autopsies, 10 req/day.
Full dataset available with Intelligence plan API key. CORS enabled.
Explore API →Academic, press, or research use? Free JSON API available — no auth required →